IMB 101 - IMBiologics
Alternative Names: IMB-101 - IMBiologics; NAV-240; OX40LxTNFα bispecific antibody - IMBiologics; OXTIMALatest Information Update: 21 Feb 2026
At a glance
- Originator HK inno.N
- Developer HK inno.N; Navigator Medicines
- Class Anti-inflammatories; Bispecific antibodies; Immunotherapies; Skin disorder therapies
- Mechanism of Action OX40 ligand inhibitors; Tumour necrosis factor alpha inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Hidradenitis suppurativa
- Phase I Autoimmune disorders; Rheumatoid arthritis